Navigation Links
Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
Date:5/20/2008

eding and stool frequency as a modified UC-DAI sub-score of 0.

Overall, a total of 341 patients with active, mild to moderate UC were analyzed as part of this post hoc analysis of an 8-week study. Patients in the Kamm study received LIALDA 2.4g/day once daily (n=84), 4.8g/day once daily (n=85), Asacol 2.4g/day three times daily (n=86); or placebo (n=86).

The post hoc analysis found that regardless of the definition used for remission, treatment with LIALDA 2.4g/day, or 4.8g/day, or Asacol 2.4g/day resulted in similar median times to symptom resolution that were shorter than placebo. The Kamm study was not designed to compare LIALDA to Asacol. Asacol was included in the study as a reference arm only.

-- Symptom resolution of rectal bleeding at the first day and first of

three days, respectively:

-- LIALDA 2.4g/day: 9 days and 18 days

-- LIALDA 4.8g/day: 9 days and 17 days

-- Placebo: 14 days and 35 days

-- Normalization of stool frequency at the first day and first of three

days, respectively:

-- LIALDA 2.4g/day: 20 days and 33 days

-- LIALDA 4.8g/day: 23 days and 38 days

-- Placebo: 38 days and 53 days

-- Resolution of both rectal bleeding and normalization of stool

frequency at the first day and first of three days, respectively:

-- LIALDA 2.4g/day: 27 days and 37 days

-- LIALDA 4.8g/day: 29 days and 45 days

-- Placebo: 44 days and 56 days

Important Safety Information for LIALDA

LIALDA tablets are indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis. Safety and effectiveness of LIALDA beyond 8 weeks have not been established.

LIALDA is contraindicated in patients with hypersensitivity to salicylates (including mesalamine) or to any of the components of LIALDA. Caution should be exercised
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Trubion Announces Preliminary Analysis of Phase IIb Results With TRU-015 in Rheumatoid Arthritis
2. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
3. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
4. Immtech Announces Interim Analysis in Phase III African Sleeping Sickness Trial
5. Analysis Shows Vernakalant Hydrochloride Injection Increases Conversion to Normal Heart Rhythm in Acute Atrial Fibrillation Patients Treated Within 48 Hours of Onset
6. New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
7. A Sociolinguistic Analysis of In-Office Dialogue Reveals Psychiatrists and Parents Have Significantly Different Perceptions on ADHD and Psychiatric Comorbidities
8. Favrille Provides Update on Timing of Analysis from Pivotal Phase 3 Clinical Trial; Reports Third Quarter 2007 Financial Results
9. Results Of VYVANSE(TM) (lisdexamfetamine dimesylate) Effect Size Analysis Presented at Major Scientific Meeting
10. Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases
11. Retrospective Analysis Finds That Initiation of Insulin Glargine in Patients With Type 2 Diabetes was Associated With a Lower Incidence Rate of Myocardial Infarction as Compared With NPH Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... COLUMBUS, Ohio, July 24, 2014  Mettler-Toledo International Inc. ... results for 2014.  Provided below are the highlights: ... in the quarter compared with the prior year. Reported ... currency. , Net earnings per diluted share as ... second quarter of 2013. Adjusted EPS was $2.57, an ...
(Date:7/24/2014)... BUENA, N.J. , July 24, 2014 ... New Jersey based specialty generic pharmaceutical company, ... resignation from its Board of Directors.  Mr. Finio has ... company, and under the terms of his acceptance of ... continue in his role as Director for IGI Laboratories, ...
(Date:7/24/2014)... Sciences, Inc. (NASDAQ: ALIM ) ("Alimera"), a ... commercialization of prescription ophthalmic pharmaceuticals, today announced that it ... financial results after the market close on Thursday, August ... the same day at 4:30 p.m. ET. ... Dan Myers , President and Chief Executive Officer, and ...
Breaking Medicine Technology:Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 2Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 3Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 4Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 5Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 6Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 7Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 8Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 9Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 10Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 11Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 12Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 13Mettler-Toledo International Inc. Reports Second Quarter 2014 Results 14IGI Laboratories, Inc. Announces Change To Its Board Of Directors 2Alimera Sciences To Release Second Quarter 2014 Results 2
... NORTH WALES, Pa., Aug. 18 AirPal ®, ... and positioning technology, has announced the expansion of its ... positioning functionality. "This announcement marks the launch ... Positioning™ systems," said Jim Weedling, President AirPal, Inc.  "Among ...
... LAUDERDALE, Fla., Aug. 18 After a lengthy ... of power mobility products and services, has selected ... to help strengthen and broaden the company,s brand ... Advertising and Daggerwing, Omnicom,s team will include Javelin ...
Cached Medicine Technology:AirPal Expands Line of Air-Activated Transfer Pads to Include Multi-Purpose Patient Positioning Functionality 2Omnicom Adds National Healthcare Giant to Client Roster 2Omnicom Adds National Healthcare Giant to Client Roster 3
(Date:7/24/2014)... Executives (ASAE) announced its 2014 Power of A Award ... of Anesthesiologists (ASA). , The ASA Global Humanitarian ... Award, one of the top honors from ASAE. GHO ... world through education on the global anesthesia crisis and ... ASA was also honored with a Power of A ...
(Date:7/24/2014)... for head and neck cancer (HNC). Evidence suggests certain cancers ... of HNC in patients with DM has not been well ... common type of cancer. It accounts for about 6 percent ... cases and 350,000 cancer deaths worldwide each year. , The ... the risk of HNC in patients with DM. The authors ...
(Date:7/24/2014)... Primary care treatment of overweight and obese preschoolers ... compared to when only the child is targeted, according ... and conducted at the University at Buffalo and Women ... study were overweight or obese and had one parent ... or obese, according to body mass index (BMI) measurements, ...
(Date:7/24/2014)... 2014 (HealthDay News) -- Drinking caffeine may worsen the ... of women as they go through menopause, new survey ... study suggests that limiting caffeine intake may be useful ... and night sweats," said researcher Dr. Stephanie Faubion, director ... in Rochester, Minn. But caffeine -- a stimulant ...
(Date:7/24/2014)... new study led by the Translational Genomics Research Institute ... and the immune system during HIV infection. , Currently, ... infect others based on their blood viral load. ... their semen despite having low levels in their blood. ... virus can be found in different parts of the ...
Breaking Medicine News(10 mins):Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Is Coffee Aggravating Your Hot Flashes? 2Health News:TGen-led study seeks to understand why some HIV-positive men are more infectious 2
... therapy changed as needed, study found , , MONDAY, May ... have only a 50-50 chance that their doctors will ... a new study finds. , Treating high blood pressure ... pressure can lead to increased risk for heart attack, ...
... Medical Center-led pilot study that showed antidepressants can significantly ... cancer patients is the focus of an article published ... the publications produced by the Journal of American Medical ... UNMCs William Lydiatt, M.D., and Bill Burke, M.D., showed ...
... new life as a stroke treatment, researchers say. , ... inhibiting white blood cells and enzymes that, at ... respectively, says Dr. David Hess, chair of the Department ... of Medicine. The broad-spectrum antibiotic also seems to reduce ...
... clinical trial led by a University of North Carolina ... an effective treatment for dysplasia in people with Barretts ... cancer. , The interim results show there is a ... placebo or sham treatment, said Dr. Nicholas Shaheen, principal ...
... International,Meeting, FAIRFAX, Va., May 19 The American ... a cancer,survivor in the Boston area who has dedicated ... the local community. The winner of the Survivor Circle ... on Tuesday, September 23,2008, at the Boston Convention and ...
... NY) Michael Brownlee, M.D., the Anita and Jack ... of Medicine of Yeshiva University, has been selected by ... prestigious David Rumbough Award for Scientific Excellence. The ... to diabetes research. Actress Dina Merrill established this ...
Cached Medicine News:Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 2Health News:Many Diabetics Don't Get Necessary Blood Pressure Treatment 3Health News:JAMA publication features study on depression and head and neck cancer 2Health News:Old antibiotic may find new life as a stroke treatment 2Health News:Old antibiotic may find new life as a stroke treatment 3Health News:Radiofrequency ablation is effective treatment for dysplasia in Barrett's esophagus 2Health News:Award Honors Boston Cancer Survivor Who Gives Back 2Health News:Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: